Supercritical fluid-mediated liposomes containing cyclosporin A for the treatment of dry eye syndrome in a rabbit model: Comparative study with the conventional cyclosporin A emulsion

International Journal of Nanomedicine

Volumn 9, Issue 1, 2014, Pages 3791-3800

  Karn, Pankaj Ranjan ^a   Do Kim, Hyun ^a,b   Kang, Han ^a,b   Sun, Bo Kyung ^a,b   Jin, Su Eon ^b   Hwang, Sung Joo ^a,b  

^a Yonsei Institute of Pharmaceutical Sciences   (South Korea)

^b Yonsei University   (South Korea)

Author keywords

Cyclosporin A; Dry eye syndrome; Liposomes; Supercritical fluid

Indexed keywords

CYCLOSPORIN; LIPOSOME;

ANIMAL; BIOLOGICAL MODEL; BLINKING; CHEMISTRY; DISEASE MODEL; DRY EYE SYNDROMES; LACRIMAL FLUID; MALE; PERMEABILITY; RABBIT;

ANIMALS; BLINKING; CYCLOSPORINE; DISEASE MODELS, ANIMAL; DRY EYE SYNDROMES; LIPOSOMES; MALE; MODELS, BIOLOGICAL; PERMEABILITY; RABBITS; TEARS;

EID: 84905985531     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S65601     Document Type: Article

References (45)

1. Javadi MA, Feizi S. Dry eye syndrome. J Ophthalmic Vis Res. 2011; 6(3):192-198.
2. Lee SY, Han SJ, Nam SM, et al. Analysis of tear cytokines and clinical correlations in Sjögren syndrome dry eye patients and non-Sjögren syndrome dry eye patients. Am J Ophthalmol. 2013;156(2):247-253.
3. Stonecipher KG, Chia J, Onyenwenyi A, Villanueva L, Hollander DA. Health claims database study of cyclosporine ophthalmic emulsion treatment patterns in dry eye patients. Ther Clin Risk Manag. 2013;9:409-415.
4. Baiza-Durán L, Medrano-Palafox J, Hernández-Quintela E, Lozano-Alcazar J, Alaníz-de la O JF. A comparative clinical trial of the efficacy of two different aqueous solutions of cyclosporine for the treatment of moderate-to-severe dry eye syndrome. Br J Ophthalmol. 2010;94(10): 1312-1315.
5. Karn PR, Cho W, Park HJ, Park JS, Hwang SJ. Characterization and stability studies of a novel liposomal cyclosporin A prepared using the supercritical fluid method: comparison with the modified conventional Bangham method. Int J Nanomedicine. 2013;8:365-377.
6. Rodriguez-Aller M, Kaufmann B, Guillarme D, et al. In vivo characterisation of a novel water-soluble cyclosporin A prodrug for the treatment of dry eye disease. Eur J Pharm Biopharm. 2012;80(3): 544-552.
7. Di Tommaso C, Valamanesh F, Miller F, et al. A novel cyclosporin A aqueous formulation for dry eye treatment: in vitro and in vivo evaluation. Invest Ophthalmol Vis Sci. 2012;53(4):2292-2299.
8. Donnenfeld E, Pflugfelder SC. Topical ophthalmic cyclosporin: pharmacology and clinical uses. Surv Ophthalmol. 2009;54(3):321-338.
9. Pflugfelder SC. Antiinflammatory therapy for dry eye. Am J Ophthalmol. 2004;137(2):337-342.
10. Wilson SE, Perry HD. Long-term resolution of chronic dry eye symptoms and signs after topical cyclosporine treatment. Ophthalmology. 2007;114(1):76-79.
11. Roberts CW, Carniglia PE, Brazzo BG. Comparison of topical cyclosporin, punctal occlusion, and a combination for the treatment of dry eye. Cornea. 2007;26(7):805-809.
12. Aksungur P, Demirbilek M, Denkbaş EB, Vandervoort J, Ludwig A, Ünlü N. Development and characterization of cyclosporin A loaded nanoparticles for ocular drug delivery: cellular toxicity, uptake, and kinetic studies. J Control Release. 2011;151(3):286-294.
13. Gupta C, Chauhan A. Ophthalmic delivery of cyclosporin A by punctual plugs. J Control Release. 2011;150(1):70-76.
14. Al-Angary A, Bayomi M, Khidr S, Al-Meshal M, Al-Dardiri M. Characterization, stability and in vivo targeting of liposomal formulations containing cyclosporin. Int J Pharm. 1995;114(2):221-225.
15. Al-Meshal MA, Khidr SH, Bayomi MA, Al-Angary AA. Oral administration of liposomes containing cyclosporin: a pharmacokinetic study. Int J Pharm. 1998;168(2):163-168.
16. Guan P, Lu Y, Qi J, et al. Enhanced oral bioavailability of cyclosporin A by liposomes containing a bile salt. Int J Nanomedicine. 2011;6: 965-974.
17. Alghadyan AA, Peyman GA, Khoobehi B, Liu KR. Liposome-bound cyclosporine: retinal toxicity after intravitreal injection. Int Ophthalmol. 1988;12(2):105-107.
18. Alghadyan AA, Peyman GA, Khoobehi B, Milner S, Liu KR. Liposomebound cyclosporine: clearance after intravitreal injection. Int Ophthalmol. 1988;12(2):109-112.
19. Milani JK, Pleyer U, Dukes A, et al. Prolongation of corneal allograft survival with liposome-encapsulated cyclosporine in the rat eye. Ophthalmology. 1993;100(6):890-896.
20. Mishra GP, Bagui M, Tamboli V, Mitra AK. Recent applications of liposomes in ophthalmic drug delivery. J Drug Deliv. 2011;2011: 863734.
21. Ebrahim S, Peyman GA, Lee PJ. Applications of liposomes in ophthalmology. Surv Ophthalmol. 2005;50(2):167-182.
22. Lallemand F, Felt-Baeyens O, Besseghir K, Behar-Cohen F, Gurny R. Cyclosporin A delivery to the eye: a pharmaceutical challenge. Eur J Pharm Biopharm. 2003;56(3):307-318.
23. Yavuz B, Bozdaǧ Pehlivan S, Ünlü N. An overview on dry eye treatment: approaches for cyclosporin A delivery. Scientific World Journal. 2012;2012:194848.
24. Hwang SJ, Karn PR, Cho W, Kang H, Sun BK, Inventors; Foundation of University-Industry Research Collaboration of Yonsei University, assignee. Ophthalmic liposome composition for treating dry eye syndrome comprising cyclosporin. Korean patent application 10-20140006954. 2014 Feb 20.
25. Shafaa MW, El Shazly LH, El Shazly AH, El gohary AA, El hossary GG. Efficacy of topically applied liposome-bound tetracycline in the treatment of dry eye model. Vet Ophthalmol. 2011;14(1):18-25.
26. Gin J, Wong VG, inventors; Visionex, assignee. Schirmer tear test. United States patent 5006310. 1991 Apr 9.
27. Diebold Y, Jarrín M, Sáez V, et al. Ocular drug delivery by liposome-chitosan nanoparticle complexes (LCS-NP). Biomaterials. 2007;28(8):1553-1564.
28. Organization for Economic Co-operation and Development. OECD Test Guideline 405: Acute Eye Irritation/Corrosion. Paris: Organization for Economic Co-operation and Development; 2012. http://ntp.niehs.nih.gov/iccvam/SuppDocs/FedDocs/OECD/OECD-TG405-2012-508.pdf. Accessed March 23, 2013.
29. Wilhelmus KR. The Draize eye test. Surv Ophthalmol. 2001;45(6): 493-515.
30. Li N, Zhuang C, Wang M, Sun X, Nie S, Pan W. Liposome coated with low molecular weight chitosan and its potential use in ocular drug delivery. Int J Pharm. 2009;379(1):131-138.
31. Li X, Nie SF, Kong J, Li N, Ju CY, Pan WS. A controlled-release ocular delivery system for ibuprofen based on nanostructured lipid carriers. Int J Pharm. 2008;363(1-2):177-182.
32. Meisner D, Mezei M. Liposome ocular delivery systems. Adv Drug Deliv Rev. 1995;16(1):75-93.
33. Karn PR, Cho W, Hwang SJ. Liposomal drug products and recent advances in the synthesis of supercritical fluid-mediated liposomes. Nanomedicine (Lond). 2013;8(9):1529-1548.
34. Allen TM, Cullis PR. Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev. 2013;65(1):36-48.
35. Liu S, Jones L, Gu FX. Nanomaterials for ocular drug delivery. Macromol Biosci. 2012;12(5):608-620.
36. Law SL, Huang KJ, Chiang CH. Acyclovir-containing liposomes for potential ocular delivery. Corneal penetration and absorption. J Control Release. 2000;63(1-2):135-140.
37. Craig JP, Purslow C, Murphy PJ, Wolffsohn JS. Effect of a liposomal spray on the pre-ocular tear film. Cont Lens Anterior Eye. 2010;33(2): 83-87.
38. Butovich IA, Lu H, McMahon A, Eule JC. Toward an animal model of the human tear film: biochemical comparison of the mouse, canine, rabbit, and human meibomian lipidomes. Invest Ophthalmol Vis Sci. 2012;53(11):6881-6896.
39. Guo LSS, Redmann CT, Radhakrishnan R, inventors; Liposome Technology, Inc., assignee. Ophthalmic liposomes. US Patent 4804539. 1989 Feb 14.
40. Lee VH, Takemoto KA, Iimoto DS. Precorneal factors influencing the ocular distribution of topically applied liposomal inulin. Curr Eye Res. 1984;3(4):585-591.
41. Dai Y, Zhou R, Liu L, Lu Y, Qi J, Wu W. Liposomes containing bile salts as novel ocular delivery systems for tacrolimus (FK506): in vitro characterization and improved corneal permeation. Int J Nanomedicine. 2013;8:1921-1933.
42. Kachi S, Hirano K, Takesue Y, Miura M. Unusual corneal deposit after the topical use of cyclosporin as eyedrops. Am J Ophthalmol. 2000; 130(5):667-669.
43. Khan W, Aldouby YH, Avramoff A, Domb AJ. Cyclosporin nanosphere formulation for ophthalmic administration. Int J Pharm. 2012; 437(1-2):275-276.
44. Okanobo A, Chauhan SK, Dastjerdi MH, Kodati S, Dana R. Efficacy of topical blockade of interleukin-1 in experimental dry eye disease. Am J Ophthalmol. 2012;154(1):63-71.
45. Huang CH. Phosphatidylcholine vesicles. Formation and physical characteristics. Biochemistry. 1969;8(1):344-352.